The Territorial Trap: Foreign Filing Restrictions for U.S. and China-Origin Inventions

Executive Summary: For inventions developed in or across the United States and China, the first patent filing decision should begin with a territorial invention-location analysis, not with inventor nationality, corporate headquarters, or preferred filing venue. The United States generally requires a foreign filing license before filing abroad for an invention made in the United States, unless a U.S. filing has been pending for at least six months without a secrecy order or another license route applies. China, by contrast, requires a confidentiality examination before filing abroad for an invention or utility model accomplished in China, meaning one whose substantive technical solution was completed in China. These rules are easy to overlook in cross-border R&D, especially where distributed teams contribute different aspects of the claimed invention. A Chinese national may create a U.S.-origin invention while in the United States, and a U.S. national may create a China-origin invention while in China. Accordingly, patent teams should conduct a claim-focused contribution analysis before filing, preserve clearance records, and avoid assuming that a U.S. provisional, Chinese first filing, or PCT application automatically resolves both countries’ national-security review requirements.

I.               Introduction

Multinational patent filing strategy often begins with familiar questions: Where is the market? Where are the competitors? Should the first filing be a U.S. provisional, a Chinese application, an EP application, or a PCT application? For inventions developed in or across the United States and China, however, a more basic question should come first: where was the invention made?

That question matters because both the United States and China restrict certain foreign patent filings before national-security review has occurred. The U.S. mechanism is generally called a foreign filing license. The Chinese analogue is usually called a confidentiality examination or confidentiality review. Although the policy rationale is similar, the two regimes differ in terminology, trigger, procedure, subject-matter scope, timing, and consequences.

The most important practical point is that neither regime is primarily an inventor-nationality rule. The United States asks whether the invention was made in the United States. China asks whether the invention or utility model was accomplished in China, meaning whether the substantive content of the technical solution was completed in China. A Chinese national can create a U.S.-origin invention while physically in the United States, and a U.S. national can create a China-origin invention while physically in China.

II.            The Shared Policy: National-Security Screening Before Foreign Disclosure

Foreign filing license laws sit at the intersection of patent prosecution, export control, national-security review, and invention-location analysis. They are not ordinary priority rules. A foreign filing license problem can arise even where the invention is patentable, the applicant owns the invention, the claims are adequately supported, and the filing satisfies the Paris Convention or PCT timing rules.

The U.S. statutory framework is found principally in 35 U.S.C. §§ 181–188 and implementing regulations in 37 C.F.R. Part 5. Section 184 restricts filing abroad for inventions made in the United States unless the applicant has obtained the required license or the statutory six-month period has passed after U.S. filing, subject to secrecy-order limitations. 35 U.S.C. § 184; 37 C.F.R. § 5.11(a), (e). The Chinese rule is found in Article 19 of the Patent Law of the People’s Republic of China, which requires confidentiality examination before filing abroad for an invention or utility model accomplished in China. Patent Law of the People’s Republic of China art. 19 (promulgated by the Standing Comm. Nat’l People’s Cong., Mar. 12, 1984, amended Oct. 17, 2020, effective June 1, 2021) [hereinafter China Patent Law].

These rules are easy to miss because they arise before the usual patent-prosecution workflow. A patent team may be focused on inventorship, ownership, export classification, priority, or claim scope, while the filing department simply implements an instruction to file first in the United States, China, Europe, or through the PCT. But if the filing sequence violates the applicable national-security clearance rule, the problem may not be curable later.

III.         The U.S. Foreign Filing License Regime

The U.S. rule applies when an application is to be filed abroad for an invention made in the United States. Under 37 C.F.R. § 5.11(a), a license from the Commissioner for Patents is required before filing an application for patent, including modifications, amendments, supplements, or divisions, or before seeking registration of a utility model, industrial design, or model, in a foreign country or foreign or international intellectual property authority, if the invention was made in the United States and either no U.S. application has been filed or a U.S. application was filed less than six months before the contemplated foreign filing. 37 C.F.R. § 5.11(a)(1)–(2).

The regulation is expressly territorial. It does not say “inventions made by U.S. citizens” or “inventions owned by U.S. companies.” It says inventions “made in the United States.” 37 C.F.R. § 5.11(a). Conversely, no license under paragraph (a) is required if the invention was not made in the United States, or if a corresponding U.S. application has been filed for at least six months and is not subject to a secrecy order. 37 C.F.R. § 5.11(e)(1)–(2).

The most common path to obtaining a U.S. foreign filing license is to file first in the USPTO. Filing a U.S. application for a U.S.-made invention is treated as including a petition for a foreign filing license, and the filing receipt or other official USPTO notice indicates whether a license has been granted. 37 C.F.R. § 5.12(a); Manual of Patent Examining Procedure § 140 (9th ed., Rev. 01.2024) [hereinafter MPEP]. The applicant may also file an express petition for a license, including where no U.S. application has yet been filed, where the filing receipt has not issued, where additional subject matter needs to be licensed, or where expedited treatment is needed. 37 C.F.R. §§ 5.12(b), 5.13, 5.14; MPEP § 140.

The U.S. rule also includes an export-control dimension. A foreign filing license authorizes certain exports of technical data for purposes related to preparing, filing, possibly filing, and prosecuting a foreign application, and for use of specified WIPO online services in preparing an international application for filing with the USPTO as receiving office. 37 C.F.R. § 5.11(b). But it is not a general export-control clearance. If technical data is exported for reasons unrelated to foreign patent filing, other export-control regimes may still apply. 37 C.F.R. § 5.11(c); MPEP § 140.

The consequences of noncompliance can be severe. Under 35 U.S.C. § 185, a person who improperly files abroad without obtaining the required license may be barred from receiving a U.S. patent, and an issued U.S. patent may be invalid unless the failure to obtain the license was through error and the patent does not disclose subject matter within the scope of 35 U.S.C. § 181. 35 U.S.C. § 185. A willful violation may also carry criminal penalties. 35 U.S.C. § 186. The USPTO also recognizes petitions for retroactive foreign filing licenses where an unlicensed foreign filing occurred through error and the regulatory requirements are satisfied. 35 U.S.C. § 184; 37 C.F.R. § 5.25; MPEP § 140.

IV.         The Chinese Confidentiality Examination Regime

China’s analogous rule is not framed as a “foreign filing license” in U.S. terminology. Article 19 of the Chinese Patent Law requires that, where any entity or individual intends to file a patent application abroad for an invention or utility model accomplished in China, the matter must first be submitted to the patent administration department under the State Council for confidentiality examination. China Patent Law art. 19.

Two features are especially important for U.S. practitioners. First, Article 19 applies to “any entity or individual.” It is not limited to Chinese nationals, Chinese companies, or Chinese-resident inventors. China Patent Law art. 19. Second, the rule is directed to inventions and utility models “accomplished in China.” Id. The current Implementing Regulations define that phrase to mean an invention or utility model for which the substantive content of the technical solution was completed within the territory of China. Implementing Regulations of the Patent Law of the People’s Republic of China art. 8 (promulgated by the State Council, June 15, 2001, amended Dec. 11, 2023) [hereinafter China Patent Law Implementing Regulations].

Article 8 of the Implementing Regulations provides the procedural routes. If an applicant intends to apply directly in a foreign country or submit an international patent application to a relevant foreign organization for an invention or utility model completed in China, the applicant must first submit a confidentiality review request and provide a detailed explanation of the technical solution. China Patent Law Implementing Regulations art. 8(1). If the applicant first files in China and later intends to file abroad or submit an international patent application to a foreign organization, the applicant must submit the confidentiality review request before the foreign filing. Id. art. 8(2). Filing an international patent application with the patent administration department under the State Council is deemed to include a confidentiality review request. Id. art. 8.

The timing rules are also specific. Under Article 9 of the Implementing Regulations, if the patent administration department, after examination, considers that the invention or utility model may involve national security or significant national interests requiring confidentiality, it must issue a confidentiality review notification within two months from submission of the request; in complex cases, that period may be extended by two additional months. China Patent Law Implementing Regulations art. 9. If confidentiality examination proceeds, a decision on whether confidentiality is required must be made within four months from submission of the request; in complex cases, that period may be extended by two months. Id.

The sanction for violating Article 19 is direct and commercially important. If a patent application for an invention or utility model is filed abroad in violation of Article 19, the invention or utility model shall not be granted a patent right when a patent application is filed in China. China Patent Law art. 19. If the violation results in disclosure of a state secret, Article 78 provides for administrative sanction and potential criminal responsibility. Id. art. 78.

V.            Key Differences Between the U.S. and Chinese Regimes

The U.S. and Chinese regimes are similar in policy but different in execution.

In the United States, the operative mechanism is a license under 35 U.S.C. § 184 and 37 C.F.R. Part 5. A U.S. application usually initiates the license review automatically, and the filing receipt or other USPTO notice indicates whether the license has been granted. 37 C.F.R. § 5.12(a); MPEP § 140. In China, the operative mechanism is a confidentiality examination under China Patent Law Article 19 and Articles 8 and 9 of the Implementing Regulations. China Patent Law art. 19; China Patent Law Implementing Regulations arts. 8–9.

The U.S. rule expressly covers applications for patents, utility models, industrial designs, or models. 37 C.F.R. § 5.11(a). The Chinese Article 19 regime is directed to inventions and utility models, not designs. China Patent Law art. 19. That distinction matters for design-heavy consumer products, where a U.S.-origin design filing may implicate 37 C.F.R. Part 5, while China Article 19 may not apply by its own terms. Other Chinese laws concerning state secrets, technology export, data security, or national security may still need to be considered.

The U.S. system contains a practical six-month route: if a corresponding U.S. application has been filed for at least six months and is not subject to a secrecy order, no license under 37 C.F.R. § 5.11(a) is required. 37 C.F.R. § 5.11(e)(2). China’s system is not structured as a U.S.-style six-month safe harbor. Rather, the applicant must request confidentiality examination before the foreign filing when Article 19 applies. China Patent Law art. 19; China Patent Law Implementing Regulations art. 8.

The U.S. system also provides for retroactive relief where the foreign filing occurred through error and the relevant requirements are met. 35 U.S.C. § 184; 37 C.F.R. § 5.25. China Article 19 should not be treated as having an equivalent U.S.-style retroactive-license mechanism. The safer Chinese practice is to obtain confidentiality examination clearance before the foreign filing.

VI.         The Difficult Case: When Is an Invention “Made” or a Technical Solution “Completed”?

The easy cases are straightforward. If all inventive activity occurs in the United States, the U.S. foreign filing license rules should be analyzed before any non-U.S. filing. See 35 U.S.C. § 184; 37 C.F.R. § 5.11(a). If all substantive development of an invention or utility model occurs in China, China’s confidentiality examination requirement should be analyzed before any foreign filing. See Patent Law of the People’s Republic of China art. 19; Implementing Regulations of the Patent Law of the People’s Republic of China art. 8. The harder cases are not single-country cases. They are distributed-development cases.

In modern collaborative R&D, the inventive story often does not map neatly onto a single location. One team may identify the technical problem. Another may propose the core algorithm. A third may design the control architecture. A fourth may validate the system experimentally. A commercial team may then add the embodiment that makes the invention valuable. In that setting, the filing-license question should not be reduced to passports, corporate headquarters, meeting location, or travel records alone. Those facts may be relevant evidence, but they are not substitutes for the legal inquiry.

For U.S. purposes, the statutory and regulatory language asks whether the invention was “made in” the United States. 35 U.S.C. § 184; 37 C.F.R. § 5.11(a). That inquiry should be informed by ordinary U.S. patent-law principles concerning conception and inventive contribution. In U.S. law, conception generally requires a definite and permanent idea of the complete and operative invention, not merely a research goal, a desired result, or a request that someone solve a problem. See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed. Cir. 1986); Burroughs Wellcome Co. v. Barr Labs., Inc., 40 F.3d 1223, 1227–28 (Fed. Cir. 1994). Thus, in a distributed project, counsel should ask where the claimed inventive concept was actually formed and who contributed the elements that made the invention complete for purposes of the claims.

For China purposes, the question is framed differently. Article 19 applies when an invention or utility model is “accomplished in China,” and the Implementing Regulations explain that this refers to an invention or utility model for which the substantive content of the technical solution was completed within China. Patent Law of the People’s Republic of China art. 19; Implementing Regulations of the Patent Law of the People’s Republic of China art. 8. That formulation directs attention to the substance of the technical solution, not merely the nationality of the inventors, the residence of the applicant, or the administrative location of the patent department.

This difference in wording matters. The U.S. inquiry tends to align naturally with the location of conception and inventive contribution. The Chinese inquiry focuses on where the substantive content of the technical solution was completed. Those inquiries will often point to the same country, but not always. For example, a U.S. team may formulate the general inventive concept, while a China-based team supplies the concrete technical architecture that makes the solution operable. Conversely, a China-based team may identify the technical solution, while a U.S. team later contributes a claim-critical improvement. In either case, a mechanical rule based on the location of the final meeting or the first patent-drafting session would be unreliable.

The better practice is to conduct a claim-focused contribution analysis before selecting the first filing venue. Counsel should identify the features that are likely to appear in the independent claims, determine who contributed those features, and map where those contributions were made. The analysis should distinguish between identifying a problem, suggesting a desired performance objective, performing routine implementation, reducing an already-conceived invention to practice, and contributing a feature that becomes part of the claimed inventive solution. See Ethicon, Inc. v. U.S. Surgical Corp., 135 F.3d 1456, 1460–61 (Fed. Cir. 1998); Burroughs Wellcome, 40 F.3d at 1227–28.

Documentation matters. In close cases, the record should include invention disclosures, meeting notes, laboratory notebooks, source-code commit histories, design-review materials, technical drawings, test protocols, email correspondence, and patent-drafting records. The goal is not merely to reconstruct where people were located on a particular date, but to determine where the legally and technically significant contribution was made. A travel calendar may show that an engineer was in Shanghai, Boston, Shenzhen, or San Jose; it does not necessarily show where the substantive inventive contribution occurred.

This analysis is especially important when the first filing is a U.S. provisional application, a Chinese invention application, or a PCT application. A U.S. provisional filing may be appropriate for an invention made in the United States, but it may be a foreign filing from China’s perspective if the substantive content of an invention or utility model was completed in China. Conversely, filing first in China may not resolve U.S. foreign filing license issues if claim-relevant inventive subject matter was made in the United States. See 35 U.S.C. § 184; 37 C.F.R. § 5.11(a); Patent Law of the People’s Republic of China art. 19; Implementing Regulations art. 8.

The practical lesson is that “where was the invention made?” is not always the same as “where did the meeting occur?” or “where was the inventor employed?” In distributed U.S.–China R&D, the safer question is more precise: where were the substantive inventive contributions made, and, for China, where was the substantive content of the technical solution completed? That question should be answered before the first filing instruction is sent.

VII.       Common Scenarios

The following scenarios apply the contribution-based approach described above. Each assumes simplified facts, but the real-world analysis should remain claim-focused: identify the substantive inventive contribution, determine where it was made, and then assess whether U.S. foreign filing license review, Chinese confidentiality examination, or both are required.

Scenario 1: U.S.-Only R&D, First Filing Desired Outside the United States

Assume all inventive work occurred in the United States, but the applicant wants to file first in Europe, China, or through a PCT application filed with a non-U.S. receiving office. Because the invention was made in the United States, a U.S. foreign filing license is generally required before the foreign filing unless a U.S. application has already been filed for at least six months and no secrecy order applies. 35 U.S.C. § 184; 37 C.F.R. § 5.11(a), (e)(2).

The usual solutions are to file first in the USPTO and confirm that the filing receipt or other official notice grants the license, file an express petition under 37 C.F.R. § 5.12(b), or wait six months after U.S. filing if no secrecy order has issued. 37 C.F.R. §§ 5.11(e)(2), 5.12; MPEP § 140.

Scenario 2: China R&D Center, U.S. Parent Wants to File a U.S. Provisional First

Assume the substantive technical content of an invention or utility model was completed in China, but the corporate patent team wants to file a U.S. provisional application first. From the Chinese perspective, the U.S. provisional is a foreign patent filing. If the invention or utility model was accomplished in China, Article 19 requires confidentiality examination before that U.S. filing. China Patent Law art. 19; China Patent Law Implementing Regulations art. 8.

The fact that a U.S. provisional application is not normally published immediately does not eliminate the Article 19 issue. The trigger is filing abroad for a China-completed invention or utility model, not publication. China Patent Law art. 19.

Scenario 3: Joint U.S.-China Inventive Contributions

Assume inventors or technical contributors in both the United States and China contributed to the claimed inventive concept. This is the hardest and most common multinational problem. U.S. law may be implicated because part of the invention was made in the United States. 37 C.F.R. § 5.11(a). Chinese law may also be implicated because the substantive content of the technical solution may have been completed, at least in part, in China. China Patent Law art. 19; China Patent Law Implementing Regulations art. 8.

In this situation, the filing team should not assume that filing first in either jurisdiction solves all problems. Filing first in the USPTO may address the U.S. license review but does not necessarily satisfy China’s confidentiality examination requirement. Filing first in China may address Chinese confidentiality examination concerns but does not automatically provide a U.S. foreign filing license for U.S.-made subject matter. The safest approach is to analyze whether both clearances are needed before filing outside either jurisdiction.

Scenario 4: Chinese National Creates the Invention While in the United States During a Meeting with a U.S. Company

Assume a Chinese national travels to the United States for a technical meeting with a U.S. company. During the meeting, the Chinese national conceives the invention, either alone or jointly with U.S. company personnel. The parties later want to file first in China, Europe, or through a PCT application filed outside the USPTO as receiving office.

The inventor’s Chinese nationality should not control the U.S. foreign filing license analysis. If the invention was made in the United States, the U.S. rule may apply. 37 C.F.R. § 5.11(a). A U.S. foreign filing license generally should be obtained before filing abroad unless no license is required because a corresponding U.S. application has been on file for at least six months without a secrecy order. 37 C.F.R. § 5.11(e)(2).

Nor should the inventor’s Chinese nationality, standing alone, trigger China Article 19. China’s statutory inquiry is whether the invention or utility model was accomplished in China. China Patent Law art. 19. If all substantive technical content was completed in the United States, Article 19 generally should not be triggered merely because the inventor is Chinese. The conclusion may change if material technical content was developed in China before the meeting, if China-based personnel contributed substantive features from China, or if state-secret, employment, or technology-transfer rules independently apply.

The lesson is straightforward: a Chinese national can create a U.S.-origin invention for foreign filing license purposes.

Scenario 5: U.S. National Creates the Invention While in China During a Meeting with a Chinese Company

Now assume a U.S. national travels to China for a technical meeting with a Chinese company. During the meeting in China, the U.S. national conceives the claimed invention, either alone or jointly with Chinese company personnel. The parties want to file first as a U.S. provisional application.

The inventor’s U.S. nationality should not control the Chinese confidentiality examination analysis. If the substantive content of the technical solution was completed in China, the invention or utility model was “completed in China” under Article 8 of the Implementing Regulations, and a confidentiality examination request should be submitted before filing the U.S. provisional. China Patent Law art. 19; China Patent Law Implementing Regulations art. 8.

A U.S. foreign filing license generally should not be required merely because the inventor is a U.S. national. If the invention was not made in the United States, no license under 37 C.F.R. § 5.11(a) is required. 37 C.F.R. § 5.11(e)(1). But the analysis changes if part of the claimed invention was conceived in the United States, if U.S.-based personnel made inventive contributions from the United States, or if later amendments add U.S.-origin subject matter.

The lesson is equally straightforward: a U.S. national can create a China-origin invention for foreign filing restriction purposes.

Scenario 6: PCT First Filing

A PCT filing can be useful, but it does not eliminate national filing-license issues. If the invention was made in the United States, filing a PCT application with the USPTO as receiving office is treated differently from filing with a foreign receiving office. 37 C.F.R. § 5.11(a); MPEP § 1832. If the invention or utility model was completed in China, filing an international patent application with the Chinese patent administration department is deemed to include a confidentiality review request. China Patent Law Implementing Regulations art. 8.

The receiving office matters. For U.S.-origin subject matter, RO/US may be a safer initial PCT route. For China-origin subject matter, a PCT filing through CNIPA may address the Chinese confidentiality review procedure because the request is deemed concurrently made. For mixed U.S.-China subject matter, counsel should evaluate whether both U.S. and Chinese clearance requirements must be satisfied before any PCT filing.

Scenario 7: Design-Heavy Product Launch

The U.S. rule expressly includes foreign applications or registrations for utility models, industrial designs, or models. 37 C.F.R. § 5.11(a). China Article 19, by contrast, refers to inventions and utility models. China Patent Law art. 19. As a result, a design filing for U.S.-made subject matter may present a U.S. foreign filing license issue, while the Chinese Article 19 confidentiality examination rule may not apply by its terms to a design-only filing.

That distinction should not be overread. Product designs can be packaged with technical features, utility-model subject matter, manufacturing methods, software, or confidential technical information. A design-first filing plan should still be screened for utility-model filings, invention filings, export controls, technology-transfer rules, and confidentiality obligations.

VIII.    Conclusion

The U.S. and Chinese foreign filing regimes share a national-security purpose, but they are not interchangeable. The U.S. regime is a foreign filing license system keyed to inventions made in the United States. The Chinese regime is a confidentiality examination system keyed to inventions and utility models accomplished in China. The most dangerous mistake is to substitute nationality, corporate headquarters, or desired filing venue for the statutory inquiry.

For U.S.-China patent families, the first filing decision should begin with a territorial invention-location analysis. A Chinese national inventing in the United States may create a U.S.-origin foreign filing license issue. A U.S. national inventing in China may create a Chinese confidentiality examination issue. In cross-border R&D, the safest question is not “Where do we want to file first?” but “Which country must clear this invention before we file anywhere else?”